Johnson & Johnson logo

Johnson & Johnson

JNJ
Healthcare|Drug Manufacturers - General|USA
$240.97
-2.07 (-0.85%)
DCF (FCF)
$109.52
Earnings Power
$76.17

Upcoming Data Readouts (17)

Jun 2026
Est. completion
NAColorectal Cancer
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
NCT05903885n=1,200
Jun 2026
Est. completion
Preeclampsia (PE)
Non-Invasive Preeclampsia Screening and Biobank
NCT06643741n=6,550
Jun 2026
Est. completion
P4Wound Closure
Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures
NCT07225101n=160
Jun 2026
Est. completion
NAHypertension
Stress and Blood Pressure Management for Caregivers
NCT05734638n=90
Jun 2026
Est. completion
P3Locally Advanced Head and Neck Squamous Cell Carcinoma
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173n=500
Aug 2026
Est. completion
P2Glioblastoma
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04049669n=130
Nov 2026
Est. completion
NACAR T-Cell Therapy
THRIVE-CAR-T Digital App
NCT06665295n=100
Dec 2026
Est. completion
Early P1Skin Basal Cell Carcinoma
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
NCT07144384n=40
Jan 2027
Est. completion
NAStroke
Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)
NCT05651945n=150
May 2027
Est. completion
P4Lymphoma, B-Cell
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200n=297
Jun 2027
Est. completion
NAStress Disorders, Post-Traumatic
A Study of a Novel EEG Neurofeedback System for PTSD Treatment
NCT06770998n=250
Jun 2027
Est. completion
NAPTSD
Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder
NCT06740487n=40
Jun 2027
Est. completion
P4Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
NCT07141004n=100
Aug 2027
Est. completion
P2Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135n=100
Aug 2027
Est. completion
NAHip Osteoarthritis
Emphasys Radiostereometric Analysis
NCT06173713n=30
Apr 2030
Est. completion
NAAnkle Arthritis
Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study
NCT00552136n=250
Oct 2030
Est. completion
P1P2Plasma Cell Disorder
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
NCT07075510n=30

Awaiting Results (7)

Trials past primary completion date but still active — data readout may be imminent.

Mar 2026
NA
Remote MS Care in Antwerp
NCT06179758
Nov 2025
NA
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
NCT06153797
Nov 2022
P2
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT03620903
Apr 2022
Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms
NCT04289480
May 2019
NA
Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function
NCT02103205
Feb 2018
NA
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
NCT02696603
Dec 2012
NA
The Nordic-Baltic Bifurcation Study IV
NCT01496638

Recent Press Releases